A Phase 1/2 interventional study of FT-002 in X-Linked Retinitis Pigmentosa (XLRP), sponsored by Frontera Therapeutics. Recruiting at 1 site in China. Open to male participants aged 8 Years to 45 Years. Per ClinicalTrials.gov, last updated 2024-07-09.
Sponsored by Frontera Therapeutics · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Retinitis Pigmentosa with a site in China — 12 open to participants now, 13 under way, 1 of them phase 3. Retinitis Pigmentosa · China.
Among the 17 studies in Retinitis Pigmentosa with a site in China, this one is the 6th largest by planned enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2024, is one of 2 in phase 1/2, reaches primary completion later than 3 of the 12 other live ones, and was the 12th registered.
278 studies on the registry are indexed under Retinitis Pigmentosa; 72 are open to participants now.
Browse Retinitis Pigmentosa studies →12 of the 17 studies in Retinitis Pigmentosa with a site in China are open now. Recruiting first, the newest first:
Zhongshan Ophthalmic Center, Sun Yat-sen University · Sites in China
Ages 18+
Chigenovo Co., Ltd · Sites in China
Ages 18+
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 18+
Zhongmou Therapeutics · Sites in China
Ages 18–65
Peking University Third Hospital · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 49 Retinitis Pigmentosa studies recruiting now, 37 (76%) set no upper age limit and 7 (14%) stop at 75 or younger; 16 take children under 18; 10 take healthy volunteers.
This study: 8 Years to 45 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 3 · Phase 3 1
First in 2005; this study’s year is marked. 2 started in 2024.
This study's planned enrollment of 32 is above the median of 27 across 179 interventional studies indexed under Retinitis Pigmentosa.
Median enrollment 25 across the 15 interventional studies, 2,149 across the 2 observational. Of the 3 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 17 have an industry lead sponsor. The 10 most frequent:
Frontera Therapeutics is the lead sponsor of 7 studies on the registry; 7 are open to participants now.
Frontera Therapeutics has 2 studies filed under Retinitis Pigmentosa — fewer than ten, so there is no comparison to draw.
4 of the studies in Retinitis Pigmentosa with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05805007Peking University Third HospitalSafety and Tolerability Study of Gene Editing Drug ZVS203e in Participants With Retinitis Pigmentosa | 2026-12 |
| NCT03944239Qi ZhouSafety and Efficacy of Subretinal Transplantation of Clinical Human Embryonic Stem Cell Derived Retinal Pigment Epitheliums in Treatment of Retinitis Pigmentosa | 2026-12-31 |
| NCT07311863Suzhou UgeneX Therapeutics Co., Ltd.UGX202 Injection in Patients With Advanced Retinitis Pigmentosa | 2027-03 |
| NCT07126470Zhongshan Ophthalmic Center, Sun Yat-sen UniversityImpact of Capsular Tension Ring on Intraocular Lens Position in Retinitis Pigmentosa Cataract Patients | 2027-08 |
Add all 4 to your calendar (.ics) → With an account.
Among the 17 studies in Retinitis Pigmentosa with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this study was to evaluate the safety, tolerability, and efficacy of one-time subretinal injection of FT-002 in male subjects (8-45 years of age) with RPGR (Retinitis Pigmentosa GTPase Regulator) gene mutation-associated X-linked retinitis pigmentosa, of XLRP. This study includes Phase I (dose escalation phase) and Phase II (dose expansion phase).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Low dose FT-002
Genetic: FT-002
High dose FT-002
Genetic: FT-002
Intraocular injection of a single dose
To evaluate the safety and tolerance of FT-002
Incidence and severity of AEs
Time frame: from FT-002 administration through up to 1 years
To evaluate the efficacy of FT-002
Changes in visual sensitivity /FST/BCVAfrom baseline
Time frame: from FT-002 administration through up to 1 years
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2024 (actual). Primary completion is estimated for Aug 2025, 16 months after the start.
Of 28 phase 1/2 interventional studies under Retinitis Pigmentosa, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 92. This study's planned 16 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Frontera Therapeutics